<DOC>
	<DOCNO>NCT00217230</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety tolerability liquid formulation CAIV-T culture confirm influenza illness adult age 60 year old . In addition study aim demonstrate superiority CAIV-T compare placebo effect economic resource .</brief_summary>
	<brief_title>Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine , Trivalent , Types A &amp; B , Live Cold-Adapted ( CAIV-T ) In Adults Aged 60 Years And Older</brief_title>
	<detailed_description>To evaluate efficacy 1 year culture-confirmed influenza-illness cause community-acquired subtypes antigenically similar contain vaccine , adult age â‰¥ 60 year enrollment , 1 dose intranasally-administered ( IN ) liquid formulation influenza virus vaccine , trivalent , type A B , live , cold-adapted ( CAIV-T ; Wyeth , Marietta , PA , USA ) compare saline placebo .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>age least 60 year old time enrollment ; determine medical history , physical examination clinical judgement eligible study . Subjects stable preexist disease , define disease require change therapy hospitalization within 12 week receipt study vaccination eligible . provide write informed consent nature study explain ; , available duration trial ( enrollment approximately November 30 , 2001 ) ; reach study staff postvaccination weekly surveillance contact [ telephone , clinic home visit ] . perceive unavailable difficult contact evaluation study visit study period ; resident nursing home longterm care facility institution receive skilled semiskilled nursing care ( refer study manual ) . An ambulatory subject resident retirement home village eligible trial . With evidence dementia severe cognitive impairment base Mini Mental State Examination ( MMSE ) score ( refer study manual ) . know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; cytotoxic agent ; receive blood product , include immunoglobulin , period six month prior vaccination conclusion study ; immunosuppressed immunocompromised individual living household ; document history hypersensitivity egg egg protein component study vaccine placebo ; administer live virus vaccine within one month prior enrollment expect receive another live virus vaccine within one month vaccination study ; intent administer investigational vaccine agent one month prior enrollment conclusion study ; , receive dose influenza treatment ( commercial investigational ) one month prior enrollment . The prophylactic use influenza antiviral permit . receive influenza vaccine 6 month enrollment , nonstudy influenza vaccine since enrollment ; medical condition opinion investigator might interfere interpretation study result ; Note : A pregnant household member consider contraindication enrollment</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>